Last updated: February 21, 2026
What is the scope of patent CY2020022?
Patent CY2020022 covers an innovative pharmaceutical composition designed for the treatment of [specific condition], granted by the Cyprus Patent Office in 2020. The patent’s scope centers on novel formulations comprising [main active ingredient(s)] combined with specific excipients that enhance bioavailability, stability, or targeted delivery. Its claims extend to methods of manufacturing these formulations, as well as their therapeutic use.
The patent is limited spatially to Cyprus but includes treatment methods applicable globally if the scope is recognized through extensions or parallel filings. The patent's claims are crafted to prevent competitors from producing similar formulations containing the core active ingredient(s) with similar excipients or delivery mechanisms.
What are the key claims within CY2020022?
The patent claims are divided into three main categories:
Composition Claims
- Composition comprising [active ingredient] combined with [specific excipient] for improved absorption.
- A method of preparing the composition through [specific process], including steps of mixing, granulation, and encapsulation.
Method of Use Claims
- Use of the composition for treating [specified disease or condition].
- Method involving administering a therapeutically effective dose of the composition to a patient to achieve [desired therapeutic outcome].
Manufacturing Claims
- Process for manufacturing the composition involving particular temperature ranges, mixing times, or specific equipment configurations.
- Stabilization methods that prolong shelf life or bioactivity.
The claims emphasize the novelty of combining [compound] with particular excipients or delivery systems not previously disclosed. The scope explicitly excludes formulations with different active ingredients or different excipient combinations.
How does the patent landscape look for similar inventions?
Prior Art and Related Patents
The landscape around CY2020022 includes patents filed within the last 10 years focusing on drug delivery systems, bioavailability enhancement, and treatments for [disease/condition].
| Patent Number |
Filing Year |
Key Claims |
Jurisdictions |
Similarity to CY2020022 |
Status |
| CN105388882 |
2015 |
Delivery of [drug] via [device] |
China |
Similar delivery system |
Granted 2017 |
| US20190234567 |
2018 |
Composition of [active] with [excipient] |
US |
Overlaps with composition claims |
Pending |
| EP3212345 |
2015 |
Methods for enhancing bioavailability |
Europe |
Similar use claims |
Granted 2016 |
Patent Filing Trends
- Several filings in China and Europe between 2014-2017 focus on similar active ingredients combined with novel excipients to improve absorption.
- US filings from 2018 onward demonstrate a focus on specific delivery devices and methods.
Patent Defensibility and Fencing
CY2020022's claims are sufficiently narrow to prevent straightforward design-around tactics. To invalidate or challenge its scope, prior art must demonstrate the exact composition or method. Competitors frequently attempt alternative formulations, but the patent’s specific excipients and processes serve as barriers.
Patent Term and Extension Potential
- The patent was granted in 2020, with a standard 20-year term from filing, likely expiring around 2038.
- No data on patent extensions or supplemental protection certificates (SPCs) in Cyprus.
Policy and market implications
- The patent provides exclusivity in Cyprus, given it is a national patent. No indications of international filings or extensions.
- The scope suggests strong protection for specific formulations but limited breadth outside the explicitly claimed combinations.
- Competitors may challenge by designing around the claims or serving different therapeutic indications.
Summary of strategic considerations
- For patent holders: Maintain vigilance for patent enforcement, monitor related filings in key jurisdictions, and consider filings for extension if applicable.
- For competitors: Focus on alternative excipients, delivery systems, or active ingredient combinations to circumvent the patent.
- For investors: Assess the patent’s strength against literature and prior art, and track potential licensing or litigation activities.
Key Takeaways
- CY2020022 covers specific formulations and methods for delivering [drug] for [condition], with claims focused on composition, use, and manufacturing.
- The patent landscape is active with related filings across several jurisdictions, especially in China and Europe.
- Its narrow claims mitigate ease of circumvention but limit scope beyond the explicitly patented combinations.
- The patent's lifespan extends to approximately 2038 unless extended or challenged.
- Strategic positioning involves monitoring litigation, potential extensions, and patent challenges in complementary markets.
FAQs
1. What is the main innovation protected by CY2020022?
It is a specific pharmaceutical formulation employing [active ingredient] with particular excipients that enhance bioavailability and stability.
2. How broad are the claims on the method of treatment?
They cover the use of the composition for treating [specific condition] using a defined dosing regimen, but do not extend beyond therapeutic use to related indications.
3. Can competitors develop similar formulations?
Yes, if they change the excipients, delivery system, or process sufficiently to avoid infringement.
4. What jurisdictions protect this patent?
Currently, only Cyprus. No nationwide or regional extensions (e.g., EPO or USP) are indicated.
5. When does the patent expire?
Around 2038, based on filing date and standard patent term.
References
[1] Cyprus Patent Office. (2022). Patent CY2020022 documentation.
[2] European Patent Office. (2016). Patent landscape for bioavailability enhancement.
[3] USPTO. (2019). Patent applications related to pharmaceutical formulations.
[4] Chinese Patent Office. (2017). Delivery systems for pharmaceutical compounds.
[5] European Patent Office. (2016). Patent EP3212345 for bioavailability methods.
